Aclarion Expands Nociscan Access Into Phoenix With Key Opinion Leader Surgeon Advisor Juan Uribe, MD
Aclarion Expands Nociscan Access Into Phoenix With Key Opinion Leader Surgeon Advisor Juan Uribe, MD
Dr. Uribe is Chief of the Division of Spinal Disorders, Volker K. H. Sonntag Chair of Spine Research, and Vice Chairman of Neurosurgery at Barrow Neurological Institute
乌里韦博士是巴罗神经学研究所脊柱疾病部主任、Volker K.H. Sonntag脊柱研究主席和神经外科副主任
Dr. Uribe Becomes Aclarion's 3rd KOL With Access to a Diagnostic Center Authorized to Perform Nociscans
Uribe 博士成为 Aclarion 的第三位关键人物，可进入授权进行诺西斯扫描的诊断中心
BROOMFIELD, CO, Jan. 22, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc. ("Aclarion" or the "Company") (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that Nociscan is now available in the greater Phoenix, AZ market at the Barrow Neurological Institute with Dr. Juan Uribe and other area physicians treating chronic low back pain.
科罗拉多州布鲁姆菲尔德，2024 年 1 月 22 日（GLOBE NEWSWIRE）— 通过 NewMediaWire — Aclarion, Inc.（“Aclarion” 或 “公司”）（纳斯达克股票代码：ACON，ACONW）是一家利用生物标志物和专有的增强智能算法帮助医生识别慢性腰痛位置的医疗技术公司。该公司今天宣布，Nociscan现已在亚利桑那州大菲尼克斯市场的巴罗神经学研究所上市，胡安·乌里韦博士和其他地区医生治疗慢性腰痛。
Dr. Uribe's practice emphasizes a comprehensive approach to treating the spine and applying minimally invasive spine surgery to complex degenerative disease. "I have dedicated my life to alleviating the pain and suffering associated with spinal disorders. Low back pain is an extremely debilitating condition that lacks a noninvasive tool helping me identify the location of a patient's pain. I am pleased Nociscan is now available in the greater Phoenix market, which will help us continue to advance more accurate diagnosis and treatments for low back pain," said Dr. Uribe.
乌里韦博士的执业重点是采用综合方法治疗脊柱，并将微创脊柱手术应用于复杂的退行性疾病。“我毕生致力于减轻与脊柱疾病相关的疼痛和痛苦。腰痛是一种极其虚弱的疾病，缺乏一种非侵入性工具来帮助我识别患者疼痛的位置。我很高兴Nociscan现在可以在大菲尼克斯市场上市，这将帮助我们继续推进更准确的腰痛诊断和治疗，” 乌里韦博士说。
Chronic low back pain (cLBP) is a leading cause of opioid addiction in the U.S. and the single most expensive diagnosis in the United States. Aclarion's Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to highlight if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies.
慢性下背痛（clBP）是美国阿片类药物成瘾的主要原因，也是美国最昂贵的诊断。Aclarion的Nociscan解决方案是第一个以无创方式帮助医生区分腰椎间盘疼痛和非疼痛的SaaS平台。Nociscan 客观地量化了已证明与椎间盘疼痛相关的化学生物标志物。生物标志物数据被输入到专有算法中，以突出椎间盘是否可能是疼痛的来源。与其他诊断工具一起使用时，Nociscan可以提供有关患者下背部疼痛位置的关键见解，从而使医生能够清晰地优化治疗策略。
"Dr. Uribe is a renowned neurosurgeon at one of the world's leading neurological institutes, Barrow," said Ryan Bond, Chief Strategy Officer of Aclarion. "Throughout Dr. Uribe's career he has rejected norms and advanced the treatment of chronic low back pain through research, education and adopting innovation. We are pleased that he and the medical community in Phoenix will now have access to Nociscan."
Aclarion首席战略官瑞安·邦德说：“乌里韦博士是世界领先神经学研究所之一巴罗的著名神经外科医生。”“在乌里韦博士的整个职业生涯中，他拒绝了规范，通过研究、教育和创新推动了慢性下背痛的治疗。我们很高兴他和菲尼克斯的医学界现在可以使用Nociscan。”
Aclarion recently announced the completion of the 1,000th commercial Nociscan exam and pointed to additional KOLs gaining access to MRIs as a key catalyst for supporting scan volume growth in 2024. Activation of the Phoenix market represents the first such key catalyst of 2024.
Aclarion最近宣布完成第1000次商业Nociscan考试，并指出获得核磁共振成像的更多KOL是支持2024年扫描量增长的关键催化剂。菲尼克斯市场的激活是2024年的第一个此类关键催化剂。